Clinical Study of Evolocumab Combined with Rosuvastatin in the Treatment of Acute Coronary Syndrome
Objective:To investigate the clinical efficacy of evolocumab combined with rosuvastatin in the treatment of acute coronary syndrome(ACS)and its effect on blood lipid parameters,inflammatory factors and serum Adropin levels.Methods:A total of 98 ACS patients treated in a hospital from January 2022 to December 2023 were selected and divided into the control group and observation group by random number table method,with 49 patients in each group.Conventional treatment by thrombolysis(urokinase for injection)and anticoagulation(low molecular weight heparin sodium for injection)was given in both groups.The control group was treated with rosuvastatin calcium tablets in addition to the conventional treatment,and the observation group was treated with evolocumab injection in addition to the treatment given in the control group.Both groups were treated continuously for 3 months.The blood lipid parameters[high-density lipoprotein cholesterol(HDL-C),triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)],myocardial injury indices[creatine kinase(CK),creatine kinase isoenzyme MB(CK-MB),cardiac troponin I(cTn I),lactate dehydrogenase(LDH),myoglobin(MYO)],inflammatory factors[interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α)],serum Adropin level,clinical response and adverse reactions were compared between the two groups.Results:After treatment,the levels of TG,TC and LDL-C were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The level of HDL-C was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The levels of CK-MB,cTn Ⅰ,LDH,CK and MYO were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The level of IL-10 was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The levels of IL-6 and TNF-α were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The serum Adropin level was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The total response rate in the observation group(91.84%)was higher than that in the control group(69.39%,P<0.05).The incidence of adverse reactions in the observation group(6.12%)was lower than that in the control group(24.49%,P<0.05).Conclusion:Evolocumab combined with rosuvastatin exhibited better clinical efficacy in the treatment of ACS with effectively reduced blood lipid levels,reduced inflammatory response and myocardial damage,and no additional risks of adverse reactions were involved.
国家科技期刊平台
NSTL
万方数据
